Myeloid Therapeutics is a clinical stage oncology company integrating the fields of mRNA-based therapeutics, immunology, and cancer biology to develop novel therapies for cancer. Myeloid's novel in vivo engineering platform programs myeloid cells in vivo to recognize tumor cells that elicit direct tumor cell killing and broad anti-tumor adaptive immunity.
EXECUTIVE BUILD
LEAD led the build of (6) executive + leadership roles at Myeloid, most completed within a (3) to (4) month timeframe, including Board Director, Stan Frankel; Myeloid’s first Chief Scientific Officer, Bruce McCreedy; Chief Technical Officer, Sadettin Ozturk; Senior Vice President of Finance, Jonathan Quick, Vice President and Global Head of CMC, Jerome Chal, and most recently Robert Hofmeister, Chief Scientific Officer.
THE CHALLENGE
LEAD was initially tasked with identifying Chief Scientific and Chief Technical Officers to lead the development of the Company’s autologous and in vivo cell therapy platforms as Myeloid approached a Series A close. Attracting versed executives to early-stage biotech companies with market-leading technical approaches can be highly challenging engagements requiring high-touch candidate conversations and experience positioning against companies with advanced funding and derisked pipelines.
THE SOLUTION
LEAD’s experience working with novel technologies in early settings ensured we relayed compelling business and scientific narratives underscoring myeloid cells’ potential to engage a full immune response, phagocytize cancer cells, and traffic + persist in the harsh tumor microenvironment. Our deep network provided access to recognized technical and manufacturing leaders with adaptive + innate immune experience and records of advancing programs to the clinic, as well as proven financial leaders with experience building in early to late stage settings.
IMPACT
Myeloid Therapeutics became the first company to dose an engineered monocyte and recently announced the close of Series B funding in support of MT-302, a clinical stage mRNA directed in vivo CAR therapy targeting challenging TROP2 epithelial tumor types.